154 related articles for article (PubMed ID: 27270560)
1. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours.
Focke CM; Decker T; van Diest PJ
Histopathology; 2016 Nov; 69(5):849-861. PubMed ID: 27270560
[TBL] [Abstract][Full Text] [Related]
2. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
3. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
4. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
5. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
6. Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?
Himuro T; Horimoto Y; Arakawa A; Tanabe M; Saito M
Int J Surg Pathol; 2016 Apr; 24(2):103-7. PubMed ID: 26353854
[TBL] [Abstract][Full Text] [Related]
7. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.
Focke CM; van Diest PJ; Decker T
Breast Cancer Res Treat; 2016 Sep; 159(2):257-63. PubMed ID: 27558625
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
9. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
10. [Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Liszka Ł
Pol J Pathol; 2016; 67(4):318-331. PubMed ID: 28547959
[TBL] [Abstract][Full Text] [Related]
11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
12. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
[TBL] [Abstract][Full Text] [Related]
13. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
14. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.
Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
20. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]